LTP forms a Co-development partnership with Aptar Pharma for SPONTAN nasal spray

LTP Pharma (ASX: LTP) has announced a Co-Development Agreement with Aptar Pharma for the global commercialization of SPONTAN, focusing on the USA and other key markets. This partnership will leverage LTP's pharmaceutical development strengths alongside Aptar's expertise in nasal spray technology, facilitating a streamlined regulatory process. The FDA application for SPONTAN Nasal Spray will utilize the 505(b)(2) expedited pathway aimed at transitioning an approved drug, Levitra (Vardenafil), to a nasal delivery system. The agreement also grants LTP access to Aptar's regulatory and analytical services, enhancing their application process and supporting market establishment and long-term innovation in healthcare solutions.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com